⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
JNJ News
Johnson & Johnson
Generalized Myasthenia Gravis Market on the Brink of Change: 8 Promising Late-Stage Drugs Signal a New Treatment Era | DelveInsight
globenewswire.com
IMVT
ROIV
CART
NVS
MRK
REGN
UCB
JNJ
AMGN
ARGX
KYMR
CABA
BMY
BHVN
Sport Beach is Back for Cannes 2026
accessnewswire.com
ADBE
PEP
EA
TTD
Z
TROW
AMZN
DDOG
F
GOOG
INTC
META
NFLX
NVDA
SPOT
STX
TSLA
CRM
SPGI
MSFT
GOOGL
FDX
CMCSA
DIS
AAPL
IBM
GE
BA
GS
JPM
BAC
WMT
COST
TGT
BABA
JD
PDD
ETSY
EBAY
PYPL
COIN
HOOD
UPST
SOFI
PLTR
SNOW
CRWD
PANW
ZS
FTNT
DD
DOW
LMT
GD
RTX
CAT
DE
AGCO
CNH
HON
MMM
XOM
CVX
SHEL
T
VZ
TMUS
LYFT
UBER
GILD
AMGN
BMY
PFE
MRK
JNJ
ABBV
LLY
NVS
AZN
BIIB
REGN
VRTX
MDLZ
KHC
CL
PG
BANC
Dr. Michelle Rozen Launches the Dr. Rozen Institute, Delivering Science-Backed Frameworks That Equip Leaders and Organizations to Navigate Volatility, Drive Execution, and Perform at the Highest Level
businesswire.com
JNJ
KO
BAC
Taiho Ventures, LLC Celebrates 10th Anniversary
prnewswire.com
JNJ
LLY
SNY
RCUS
The Psoriasis Clinical Trial Pipeline Boom as 90+ Companies are in the Race for Better Treatments | DelveInsight
globenewswire.com
JNJ
PFE
ABBV
LLY
AMGN
INCY
GILD
BHC
AZN
SUN
Form 8-K
sec.gov
JNJ
Johnson & Johnson Announces 64 th Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 3.1%
businesswire.com
JNJ
Johnson & Johnson reports Q1 2026 results, raises 2026 outlook
businesswire.com
JNJ
Mestag Therapeutics Selected to Present Targeted LTBR Agonist MST‑0312 in Late‑Breaking Session at AACR Annual Meeting
globenewswire.com
MRK
JNJ
B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Report 2026 - Worth $18.75 Billion in 2026, the Market is Expected to Reach $44.29 Billion by 2030
globenewswire.com
JNJ
AZN
BMY
NVS
GSK
AMGN